DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis
USA - NYSE:DBD - US2536512021 - Common Stock
65.09 USD
-0.2 (-0.31%)
65.09 USD
0 (0%)
Overall DBD gets a fundamental rating of 4 out of 10. We evaluated DBD against 35 industry peers in the Technology Hardware, Storage & Peripherals industry. Both the profitability and the financial health of DBD get a neutral evaluation. Nothing too spectacular is happening here. DBD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year DBD was profitable.
In the past year DBD had a positive cash flow from operations.
DBD had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: DBD reported negative operating cash flow in multiple years.
1.2 Ratios
DBD has a Return On Assets (1.36%) which is comparable to the rest of the industry.
The Return On Equity of DBD (4.57%) is better than 71.43% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.85%, DBD is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for DBD is significantly below the industry average of 16.16%.
The last Return On Invested Capital (8.85%) for DBD is above the 3 year average (5.12%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROIC | 8.85% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
1.3 Margins
DBD has a Profit Margin of 1.37%. This is comparable to the rest of the industry: DBD outperforms 60.00% of its industry peers.
With a decent Operating Margin value of 7.47%, DBD is doing good in the industry, outperforming 77.14% of the companies in the same industry.
In the last couple of years the Operating Margin of DBD has grown nicely.
Looking at the Gross Margin, with a value of 25.48%, DBD is in line with its industry, outperforming 42.86% of the companies in the same industry.
In the last couple of years the Gross Margin of DBD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% |
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DBD is destroying value.
DBD has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for DBD has been reduced compared to 5 years ago.
DBD has a better debt/assets ratio than last year.
2.2 Solvency
DBD has an Altman-Z score of 1.95. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 1.95, DBD perfoms like the industry average, outperforming 54.29% of the companies in the same industry.
The Debt to FCF ratio of DBD is 3.71, which is a good value as it means it would take DBD, 3.71 years of fcf income to pay off all of its debts.
DBD has a Debt to FCF ratio of 3.71. This is in the better half of the industry: DBD outperforms 68.57% of its industry peers.
DBD has a Debt/Equity ratio of 0.84. This is a neutral value indicating DBD is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.84, DBD is not doing good in the industry: 62.86% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Altman-Z | 1.95 |
ROIC/WACC0.94
WACC9.38%
2.3 Liquidity
DBD has a Current Ratio of 1.36. This is a normal value and indicates that DBD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.36, DBD is in line with its industry, outperforming 48.57% of the companies in the same industry.
A Quick Ratio of 0.89 indicates that DBD may have some problems paying its short term obligations.
The Quick ratio of DBD (0.89) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
DBD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.07%.
The Earnings Per Share has been growing by 69.69% on average over the past years. This is a very strong growth
DBD shows a decrease in Revenue. In the last year, the revenue decreased by -2.86%.
The Revenue has been decreasing by -3.18% on average over the past years.
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
3.2 Future
DBD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.87% yearly.
DBD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.83% yearly.
EPS Next Y-3.97%
EPS Next 2Y13.81%
EPS Next 3Y11.87%
EPS Next 5YN/A
Revenue Next Year2.09%
Revenue Next 2Y2.32%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 17.78 indicates a rather expensive valuation of DBD.
DBD's Price/Earnings ratio is a bit cheaper when compared to the industry. DBD is cheaper than 77.14% of the companies in the same industry.
When comparing the Price/Earnings ratio of DBD to the average of the S&P500 Index (25.89), we can say DBD is valued slightly cheaper.
Based on the Price/Forward Earnings ratio of 13.02, the valuation of DBD can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DBD indicates a somewhat cheap valuation: DBD is cheaper than 65.71% of the companies listed in the same industry.
DBD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.78 | ||
| Fwd PE | 13.02 |
4.2 Price Multiples
DBD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DBD is cheaper than 94.29% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, DBD is valued cheaply inside the industry as 82.86% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.48 | ||
| EV/EBITDA | 7.4 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.81%
EPS Next 3Y11.87%
5. Dividend
5.1 Amount
No dividends for DBD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
65.09
-0.2 (-0.31%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners105.22%
Inst Owner Change-2.7%
Ins Owners1.78%
Ins Owner Change0%
Market Cap2.38B
Revenue(TTM)3.69B
Net Income(TTM)50.60M
Analysts82.86
Price Target77.18 (18.57%)
Short Float %2.38%
Short Ratio4.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.97%
Min EPS beat(2)46.39%
Max EPS beat(2)59.55%
EPS beat(4)3
Avg EPS beat(4)24.69%
Min EPS beat(4)-8.92%
Max EPS beat(4)59.55%
EPS beat(8)6
Avg EPS beat(8)71.52%
EPS beat(12)8
Avg EPS beat(12)-72.18%
EPS beat(16)9
Avg EPS beat(16)-86.09%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)0.15%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.83%
PT rev (1m)0%
PT rev (3m)4.61%
EPS NQ rev (1m)7.83%
EPS NQ rev (3m)16.15%
EPS NY rev (1m)-0.41%
EPS NY rev (3m)4.56%
Revenue NQ rev (1m)-0.97%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.78 | ||
| Fwd PE | 13.02 | ||
| P/S | 0.65 | ||
| P/FCF | 9.48 | ||
| P/OCF | 8.53 | ||
| P/B | 2.15 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.4 |
EPS(TTM)3.66
EY5.62%
EPS(NY)5
Fwd EY7.68%
FCF(TTM)6.87
FCFY10.55%
OCF(TTM)7.63
OCFY11.72%
SpS100.75
BVpS30.23
TBVpS-9.36
PEG (NY)N/A
PEG (5Y)N/A
Graham Number49.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROCE | 11.2% | ||
| ROIC | 8.85% | ||
| ROICexc | 9.91% | ||
| ROICexgc | 29.15% | ||
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% | ||
| FCFM | 6.82% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexgc growth 3Y-11.73%
ROICexgc growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Debt/EBITDA | 2.28 | ||
| Cap/Depr | 20.59% | ||
| Cap/Sales | 0.75% | ||
| Interest Coverage | 2.89 | ||
| Cash Conversion | 68.06% | ||
| Profit Quality | 497.23% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | 1.95 |
F-Score7
WACC9.38%
ROIC/WACC0.94
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
EPS Next Y-3.97%
EPS Next 2Y13.81%
EPS Next 3Y11.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
Revenue Next Year2.09%
Revenue Next 2Y2.32%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.77%
EBIT Next 3Y13.69%
EBIT Next 5YN/A
FCF growth 1Y171.3%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y186.31%
OCF growth 3Y6.68%
OCF growth 5Y26.59%
DIEBOLD NIXDORF INC / DBD FAQ
What is the fundamental rating for DBD stock?
ChartMill assigns a fundamental rating of 4 / 10 to DBD.
What is the valuation status for DBD stock?
ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.
What is the profitability of DBD stock?
DIEBOLD NIXDORF INC (DBD) has a profitability rating of 5 / 10.
How financially healthy is DIEBOLD NIXDORF INC?
The financial health rating of DIEBOLD NIXDORF INC (DBD) is 4 / 10.
Can you provide the dividend sustainability for DBD stock?
The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.